Fierce Biotech1 min read
saveLilly cans early experimental obesity drug after ‘high bar’ not met
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
comments(0)
5-min edit window · permanent after that